Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T-cell therapies for T-cell lymphoma.
Toner K, Bollard CM, Dave H. Toner K, et al. Among authors: dave h. Cytotherapy. 2019 Sep;21(9):935-942. doi: 10.1016/j.jcyt.2019.04.058. Epub 2019 Jul 16. Cytotherapy. 2019. PMID: 31320195 Review.
ROR1 and ROR2-novel targets for neuroblastoma.
Dave H, Butcher D, Anver M, Bollard CM. Dave H, et al. Pediatr Hematol Oncol. 2019 Sep;36(6):352-364. doi: 10.1080/08880018.2019.1646365. Epub 2019 Aug 23. Pediatr Hematol Oncol. 2019. PMID: 31441359
Driving the CAR to the Bone Marrow Transplant Program.
Dave H, Jerkins L, Hanley PJ, Bollard CM, Jacobsohn D. Dave H, et al. Curr Hematol Malig Rep. 2019 Dec;14(6):561-569. doi: 10.1007/s11899-019-00544-6. Curr Hematol Malig Rep. 2019. PMID: 31643018 Review.
Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults.
Dreyzin A, Jacobsohn D, Angiolillo A, Wistinghausen B, Schore RJ, Perez E, Wells E, Terao J, Bonifant C, Rohatgi R, Dave H, Vatsayan A. Dreyzin A, et al. Among authors: dave h. Pediatr Hematol Oncol. 2022 May;39(4):370-378. doi: 10.1080/08880018.2021.1988012. Epub 2021 Oct 21. Pediatr Hematol Oncol. 2022. PMID: 34672243 No abstract available.
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.
Kinoshita H, Cooke KR, Grant M, Stanojevic M, Cruz CR, Keller M, Fortiz MF, Hoq F, Lang H, Barrett AJ, Liang H, Tanna J, Zhang N, Shibli A, Datar A, Fulton K, Kukadiya D, Zhang A, Williams KM, Dave H, Dome JS, Jacobsohn D, Hanley PJ, Jones RJ, Bollard CM. Kinoshita H, et al. Among authors: dave h. Blood Adv. 2022 Apr 26;6(8):2520-2534. doi: 10.1182/bloodadvances.2021006831. Blood Adv. 2022. PMID: 35244681 Free PMC article. Clinical Trial.
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.
Forlenza CJ, Rosenzweig J, Mauguen A, Buhtoiarov I, Cuglievan B, Dave H, Deyell RJ, Flerlage JE, Franklin AK, Krajewski J, Leger KJ, Marks LJ, Norris RE, Pacheco M, Willen F, Yan AP, Harker-Murray PD, Giulino-Roth L. Forlenza CJ, et al. Among authors: dave h. Blood Adv. 2023 Jul 11;7(13):3225-3231. doi: 10.1182/bloodadvances.2022009323. Blood Adv. 2023. PMID: 36897253 Free PMC article.
Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells.
Holland EM, Gonzalez C, Levy E, Valera VA, Chalfin H, Klicka-Skeels J, Yates B, Kleiner DE, Hadigan C, Dave H, Shalabi H, Hickstein DD, Su HC, Grimley M, Freeman AF, Shah NN. Holland EM, et al. Among authors: dave h. Front Immunol. 2021 Dec 17;12:801281. doi: 10.3389/fimmu.2021.801281. eCollection 2021. Front Immunol. 2021. PMID: 34975916 Free PMC article.
308 results